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We report an open-label, prospective, crossover study involving 184 post-menopausal women experiencing hot flushes on adjuvant
tamoxifen (T). Six weeks after switching to an AI, the primary end point, hot flush score, improved by 47.3% (Po0.001) compared to
those reported on T. The mean mood rating scale (MRS) score improved by 9.7% (P¼0.01). The total mean combined FACT
(bþes) score improved from 134.2 (95% CI ±2.96) to 143.5 (95% CI ±2.96 o0.001), and the endocrine subscale improved by
9.8% from 51.73 (95% CI ±1.38) to 57.34 (CI ±1.38, Po0.001). At 6 weeks, significantly more women chose to remain on an AI:
133 (72%), vs 40 (22%) (Po0.001) preferring T. At 3 months, 107 (58%) preferred to remain on an AI, 55(30%) on T, and 22 (12%)
withdrew. The overall arthralgia rate at 3 months was 47% on AI and 30% on T (P¼0.001). In all 182 (99%) women reported
appreciating the opportunity to experience both drugs. These data suggest that if patients suffering significant adverse effects on T are
given the opportunity to try an AI, this empowers them to prioritise relative side-effects, improving wellbeing in a significant
proportion. These data also highlight the need for hospital follow-up in this intolerant cohort.
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The routine adjuvant endocrine standard of care for post
menopausal women with oestrogen receptor positive breast cancer
has shifted towards including an aromatase inhibitors (AI), following
the evidence presented in five international trials demonstrating
improved disease-free survival with AI containing regimens,
compared to tamoxifen alone (Baum, 2001; Mouridsen et al,2 0 0 1 ;
Coombes et al, 2004; Boccardo et al, 2005; Jakesz et al, 2005).
It is, however, unlikely that all post menopausal women,
particularly those with a good prognosis, where the relapse rate
is low on either drug, have a clinically relevant advantage (Baum,
2001). Subgroups of patients have been identified who would
benefit the most from AIs over tamoxifen, and particularly benefit
from initial selection rather than sequencing a switch at 2 years.
These include pathological prognostic factors which predict a
higher and earlier relapse rate, such as histological grade, presence
of vascular invasion, tumour size and number of positive axillary
nodes (Mauriac et al, 2007); Biological molecular markers such a
Cerb2, Ki67, CYP-2D6, level of oestrogen receptor positivity,
progesterone receptor negativity (Ellis et al, 2001; Mauriac et al,
2007); Patient-related factors such as a history of thromboembolic
disease, risk of uterine carcinoma or osteoporosis (Ellis et al, 2001;
Lonning et al, 2005; Mauriac et al, 2007). The roles played by
quality of life, tolerance and patient preference in the choice for
either AI or tamoxifen; however, has not been formally established
previously.
Menopausal symptoms and overall quality of life have been
extensively investigated within adjuvant breast cancer studies
(Baum, 2001; Coombes et al, 2004; BIG 1-98 Collaborative Group,
2005; Boccardo et al, 2005; Jakesz et al, 2005), with particular
scrutiny within the ATAC (Fallowfield et al, 2004a) and IES
(Fallowfield et al, 2006) trials. In these studies arthralgia and
vaginal dryness was more prevalent with AIs and night sweats and
vaginal discharge with tamoxifen but there was no difference in
overall quality of life. Most women in these studies, fortunately, had
no significant menopausal symptoms on either treatment. In daily
practise, however, the clinically more relevant but unanswered
question, was whether switching to an AI in the 30% already
intolerant of tamoxifen improved or compromised quality of life.
This study assessed the short-term effect on hot flushes, mood
and quality of life, and the longer-term effect on arthralgia and
preference for tamoxifen or AI, subsequent to giving patients
personal experience of both drugs within a prospective crossover
design. The results aimed to supplement existing histological and
patient oriented factors, to aid the decision for either early
switching to AI or continuing tamoxifen.
METHODOLOGY
This open-label, crossover trial assessed post menopausal women
with oestrogen receptor positive breast cancer, experiencing
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stroublesome hot flushes while taking adjuvant tamoxifen. One
hundred and eighty four women were recruited between March
2005 and February 2007 at the Primrose Oncology Research Unit,
Bedford Hospital, UK and Russells Hall Hospital, Dudley, UK.
Ethics approval was sought, and given, for this study.
Patient selection
All 184 women gave written informed consent and had been taking
adjuvant tamoxifen for at least 3 months prior to trial entry. The
average age was 58.8 years (range, 40.6–88.7 years). The average
time on tamoxifen was 15.5 months (3–62 months). The average
time from diagnosis to switching to an AI was 20.34 months
(range, 9–88 months), 54 (29%) had received adjuvant chemo-
therapy. Patients had a histological or cytological evidence of
breast cancer which demonstrated oestrogen-receptor (ER)
positivity and were post menopausal at the time of initiation
of AI, as defined by; no spontaneous menses for at least 2 years, or
spontaneous menses within the past 2 years, but amenorrhoeic for
at least 12 months and oestrodiol, LH and FSH values according to
the definition of postmenopausal normal range of the laboratory
involved; or bilateral oophorectomy or radiation castration and
amenorrheic for at least 3 months or medical oophorectomy with
administration of LHRH agonists. In all 48 (26%) were deemed to
be menopausal when they first started taking adjuvant tamoxifen
patients but then met the definition of postmenopausal at trial
entry. Patients scored 43 on the NCI toxicity score or had average
of 14 significant hot flushes per week. All women had tried, or were
offered, lifestyle advice for hot flushes, including our written
guidance sheet (‘coping with hot flushes’ – available on
www.cancernet.co.uk). No women were taking venlafaxine or
clonidine at trial entry. Many women had tried over the counter
remedies for hot flushes (evening Primrose Oil, Black Cohosh) but
were excluded if these started within 1 month before the trial
period, otherwise these were allowed as long as they continued
unchanged.
Tolerance assessment
Hot flushes score The hot flushes diary (HFD) and scoring system
used as the primary end point in this study were originally
developed and validated by Sloan et al (2001). The HFD is an
internationally accepted tool for evaluating and comparing hot
flushes strategies, and has been used in a number of randomised
trials such as those involving venlafaxine, clonidine and fluoxetine
(Loprinzi et al, 2000, 2002; Loibl et al, 2007). The scoring system
gives an indication of frequency and severity by grading hot
flushes into mild, moderate, severe and very severe, over a 24-h
period. In this study, as these forms were self completed by
patients at home, they were also given a leaflet defining the grades
of hot flushes to help them complete the HFD. As recommended in
previous validation studies, despite these grading systems, it was
still ultimately the patient’s own interpretation of severity that was
scored. In other words, if a woman told us she had a severe hot
flush, we did not feel that it was appropriate for us to tell her it was
only a mild hot flush.
Quality of life The Functional Assessment of Cancer Therapy
(FACT), breast version with Endocrine Symptom add-ons (FACT-
BþES) was used (Cella, 1997). This questionnaire covers physical
as well as psychological symptoms, and includes a component
designed specifically for women with breast cancer who receive
hormonal therapy. The FACT-ES has been validated in the
advanced breast cancer setting, and has been shown to have good
internal consistency, reliability, patient acceptability and sensiti-
vity to clinically significant change (Cella, 1997). It has been used
in the majority of large adjuvant AI studies (Coombes et al, 2004;
Fallowfield et al, 2004a).
The Mood Rating Scale The Mood Rating Scale (MRS) is a self-
reported measure of normal mood, which consists of six 150mm
visual analogue subscales with defined anchor points. The
subscales are: tense-relaxed, sad-happy, tired-energetic, con-
fused-clear headed, irritable-easy-going, unsure-confident
(Anderson et al, 2000). The six subscales can be summated to
obtain a single total score. Reliability and validity have been found
to be good (Anderson et al, 2000), and the scale has been shown to
be responsive to the effects of cancer therapies (Walker et al, 1997,
1999a), psychological interventions (Walker et al, 1999b) and
work-induced stress. It takes approximately one minute to
complete (Anderson et al, 2000).
The patient preference questionnaire The patient preference
questionnaire was originally developed by one of the trial
committee as a tool to formalise and grade the strength of a
patient’s choice (Thomas et al, 1999). It has been used as an end
point in a subsequent crossover trial involving AIs, and
consistently correlated with quality of life and degree of side
effects (Thomas et al, 2004). Patients are asked to indicate which
drug they tolerated better overall, the reasons for this choice,
the level of confidence in their decision, and their general views on
the appropriateness of being asked the question. Patient preference
has been used in a number of other trials on subjects ranging from
oral vs i.v. chemotherapy, to choices between chemotherapy and
hormone therapies (Liu et al, 1997; Young et al, 1999; Fallowfield
et al, 2004b).
Arthralgia grading system The NCI system was used, which
grades severity into mild, moderate, severe and very severe
(National Cancer Institute, 1999).
Study design
Following written informed consent obtained while taking
tamoxifen 20mg per day, women completed a 1-week HFD, the
FACT-BþES questionnaire, an MRS and an NCI arthralgia
grading scale. They were then switched to an AI. The same
questionnaires plus a patient preference questionnaire (PPQ) were
given to patients for completion at home, and they were asked to
post back to the trial centre (to minimise social compliance
effects). For the first 104 patients in the study, letrozole 2.5mg per
day was prescribed: the next 80 patients were given exemestane
25mg per day. The women either continued on their prescribed AI
or changed back to tamoxifen, based on their patient preference
and quality of life questionnaires. A further arthralgia NCI grading
score and PPQ was completed by patients at 3 months. At any
stage after the initial 6-week trial, women were given the
opportunity to switch back to tamoxifen if they subsequently
developed troublesome side effects on their AI, and in each case
the trial office was informed. All women who chose an AI were
given ‘Lifestyle & AI’ guidance sheet (available from www.
cancernet.co.uk/bonehealth.htm) and their names were entered
into the standard bone density surveillance programme.
Statistical considerations The methodology and analysis was
conducted at Cranfield University. The primary end point was the
hot flush score (HFS intensity   number as assessed by the HFD).
It was intended that both the letrozole and exemestane phases were
statistically and independently powered .
Sample size consideration: The number of patients for the first
(letrozole) phase was determined using classic power analysis
characteristics, based on previous studies in populations of
patients with hot flushes (Loprinzi et al, 2000, 2002; Sloan et al,
2001). In these trials, with 50 patients per group, the studies had
80% power to detect differences in average hot flush activity of 0.6
s.d. using a standard two-sample t-test with a two-sided type I
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serror rate of 5%. Hence, 50 patients per treatment arm provided an
80% power to detect an average shift of 1.2 hot flushes per day or a
hot flush score of three units per day. Smaller differences were
regarded as not clinically significant. Other trials using similar
methodologies had statistically proven benefits of hot flush
remedies using similar patient numbers (Loprinzi et al, 2000,
2002; Sloan et al, 2001). The use of a crossover design, in this
study, increased power as patients acted as their own controls.
Placebo effect consideration: It has been recognised in previous
hot flush studies that a placebo effect may reduce hot flush activity
up to approximately 25%, that is, to 75% of baseline (Loprinzi
et al, 2000, 2002; Sloan et al, 2001). In view of this placebo effect, a
further 30 patients were added, or required, to ensure a minimum
of 80% power to detect a difference in average hot flush activity of
0.6 s.d. (a reduction of 25% plus 1.2 hot flushes per day or
a reduction of the score by 25% plus a score of three units) with a
type 1 error rate of 5%. That is, if a woman has six hot flushes per
day, a reduction to an average of 3.3 would be regarded as
significant. As an extra reassurance in the first letrozole phase, a
further 20 patients were added.
Because an interim analysis of this first phase (letrozole)
comfortably reached statistical significance, the second (exemes-
tane) phase adhered to the precise power recommendation of 80
patients.
Statistical analysis: The HFS, MRS and FACT-BþES were
analysed using parametric analysis of variance. This was
considered the most robust method, as even with non-normal
data, the estimated least square means and their confidence
intervals of these data were sound. Retrospective analysis of errors
showed that there was no serious departure from normally
distributed errors, and there was constant variance across all the
predicted means. The total FACT (bþes), its six subscales were
also analysed using the analysis of variance method with all the
considerations made according to the original FACT guidance
manual. Similarly, the MRS data was analysed using analysis of
variance. Pearson w
2 tests were used to analyse the PPQ and
arthralgia scores.
RESULTS
One hundred and eighty-four patients entered the study. One
patient had demonstrated signs of relapse by 6 weeks, and by 3
months, five in total had relapsed. All completed their ques-
tionnaires and were included in the analysis. The data was
analysed in three separate groups; all patients combined;
the letrozole phase alone, and the exemestane phase alone
(Tables 1–3). During the recruitment period for this trial, only
two further eligible patients declined trial entry, suggesting the
trial cohort closely reflected routine oncology practise.
Hot flushes
The severity of hot flushes, following 6 weeks AI, almost halved
from those experienced on tamoxifen, as measured by the HFS
(47.3%, Po0.001) (Table 1, Figure 1). Among the 133 (72%) who
chose AI, the difference in HFS was understandably even larger at
6 weeks (Po0.0001).
Quality of life
The total mean combined FACT (bþes) score improved by 6.5%,
from 134.2 (95% CI ±2.96), to 143.5 (95% CI ±2.96, Po0.001).
The endocrine subscale improved by 9.8% from 51.73 (95% CI
±1.38) to 57.34 (95% CI ±1.38, Po0.001). All other subscales also
reached significance (Table 1, Figures 2 and 3).
Mood
Total MRS scores, improved by 9.7% from 49.4 (95% CI ±2.48) to
54.7mm (95% CI ±2.48, P¼0.005) (Table 1, Figure 4).
Patient preference
At six weeks, 133 (72%) preferred to remain on an AI as they felt
their menopausal symptoms and other side effects were better.
Forty (22%) patients felt that they were better on tamoxifen and 11
(6%) discontinued adjuvant hormones altogether as they decided
the side effects on either hormone did not justify their adjuvant
benefits. At or after 3 months, 107 (58%) remained on an AI, 55
(30%) stayed on tamoxifen, and 19 (10.3%) of those originally
choosing an AI resumed tamoxifen, primarily due to the
Table 1 Results of hot flushes, mood and qol before and after 6 weeks
of AI
(n¼104) Tamoxifen Letrozole % Difference (P)
HFS 97.0±13.13
a 52.1±13.13 46.3%
b (P¼0.001)
Total FACT-b+es 132.7±3.92 142.1±3.92 6.7% (P¼0.01)
FACT-es 50.65±1.83 56.34±1.83 10.1% (P¼0.01)
MRS (mm) 49.6±3.29 54.9±3.29 9.6% (P¼0.004)
(n¼80) Tamoxifen Exemestane Difference (P)
HFS 70.7±8.22 36±8.22 49% (Po0.001)
Total FACT-b+es 136±4.49 145.4±4.49 4.9% (P¼0.001)
FACT-es 53.12±2.09 58.7±2.09 9.5% (Po0.001)
MRS (mm) 49.1±3.78 54.5±3.78 9.6% (P¼0.005)
(n¼184) Tamoxifen Combined AI Difference (P)
HFS 85.6±9.90 45.1±9.90 47.3% (Po0.001)
Total FACT-b+es 134.2±2.96 143.5±2.96 6.5% (P¼0.001)
FACT-es 51.73±1.38 57.34±1.38 9.8% (Po0.001)
MRS (mm) 49.4±2.48 54.7±2.48 9.7% (P¼0.01)
aFigures represent 95% confidence intervals (± 2 s.e. from the mean).
b% difference
is subtraction of mean on T from the mean on AI/by the highest of the two values
(e.g. 97–52.1/97¼46.3%).
Table 2 Patient’s preference for adjuvant hormone therapy at 6 weeks
and X3 months
Start (n¼104) Tamoxifen (T) Letrozole (L) Difference
a (P)
At 6 weeks
8 (8%) withdrew
b
26% (25/96) 74% (71/96) 48% (Po0.001)
X3 months
16 (15%) withdrew
b
31% (27/89) 69% (61/89) 38% (Po0.001)
Start (n¼80) Tamoxifen (T) Exemestane (E) Difference (P)
At 6 weeks
3 (4%) withdrew
b
19% (15/77) 81% (62/77) 62% (Po0.001)
X3 months
6 (7%) withdrew
b
38% (28/74) 62% (46/74) 24% (P¼0.036)
Start (n¼184) Tamoxifen (T) Combined AI Difference (P)
At 6 weeks
11 (6%) withdrew
b
23% (40/173) 77% (133/173) 54% (Po0.001)
X3 months
22 (12%) withdrew
b
34% (55/162) 66% (107/162) 32% (Po0.001)
aThe % difference is subtraction of percentage on T from the percentage on AI.
b22
(12%) patients withdrew by 3 months, 5 (2.7%) because they had relapsed, 17 (9.2%)
withdrew for intolerance. A further 19 (10.3%) switched back to tamoxifen from an
AI (4 from L, 15 from E), two patients later switched to AI at 3 months (1 L, 1 E).
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sdevelopment of troublesome arthralgia. One switched from
tamoxifen to exemestane. Twenty-two (12%) women, following
discussion chose to discontinue hormone therapy altogether
(Table 2).
Arthralgia
The overall arthralgia rate among the 173 still in the study after 6
weeks (11 had withdrawn), and choosing an AI was 47% during AI
administration, and those on tamoxifen was 30% (Pearson w
2,
P¼0.001). This was mainly due to the difference in severe
arthralgia (T 0% vs AI 13%), as there was no significant difference
in the mild to moderate rates (Table 3). The same trends were seen
in the individual analysis of letrozole and exemestane.
One hundred and eighty (98%) patients indicated on the final
questionnaire that they appreciated the opportunity to experience
both drugs, and to be able to make choices for themselves between
hot flushes and arthralgia.
Although not initially part of the analysis plan, a direct
comparison of letrozole vs exemestane showed no difference
between them in any predetermined trial end point category.
DISCUSSION
Menopausal symptoms, particularly hot flushes, significantly
impair quality of life in women with breast cancer (Carpenter
et al, 1998; Loprinzi et al, 2002; Fallowfield et al, 2004b;
Table 3 Arthralgia rate at or after 3 months of the chosen hormone
therapy
Arthralgia-3
months
Chosen hormone
n¼173 after
6weeks
a
Tamoxifen
(n¼40)
Both AI
(n¼133)
Difference
(P)
None 28 (70%)
b 70 (53%) 17% (P¼0.001)
Mild arthralgia 10 (25%) 30 (22%) 3% (ns)
Moderate
arthralgia
2 (5%) 16 (12%) 7% (ns)
Severe
arthralgia
0 (0%) 17 (13%) 13% (P¼0.05)
Overall
arthralgia
12 (30%) 63 (47%) 17% (P¼0.001)
aEleven of the 184 patients had withdrawn at 6 weeks.
bFor descriptive purposes the
percentages of arthralgia for T or AI written in each colomn is based on n for each
column whereas for the Pearson w
2 analysis n was 173.
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Figure 1 Tamoxifen vs AI hot flushes total intensity. Vertical bars denote
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sLoibl et al, 2007), who have a significantly higher incidence of
these symptoms than the general population (Carpenter et al,
1998). Premenopausal women may have undergone premature
menopause from chemotherapy or ovarian ablation, and post
menopausal women can endure sudden interruption of their
hormone replacement therapy (HRT), causing a recognised
rebound to severe climacteric symptoms (Jensen and Christiansen,
1983). On top of this, they are prescribed drugs such as tamoxifen
and aromatase inhibitors, which make them worse. The most
widely used non-oestrogenic therapeutic interventions for hot
flushes in women with breast cancer, include progestogens,
clonidine and venlafaxine (Carpenter et al, 1998; Loprinzi et al,
2000, 2002; Sloan et al, 2001; Loibl et al, 2007). A low dose of
progesterone such as medroxyprogesterone acetate; however, can
cause weight gain and increase the risk of thromboembolus, and
the longer term risks of its addition to tamoxifen are uncertain
(Carpenter et al, 1998). Clonidine has limited success but can cause
troublesome adverse effects of its own (Goldberg et al, 1994).
Venlafaxine has recently been shown to be more affective than
clonidine, but women are apprehensive about starting long term
antidepressants (Loprinzi et al, 2000; Loibl et al, 2007). Lifestyle
advice such as sensible clothing and avoiding stimulants can be
helpful (Sloan et al, 2001), and hence all patients in this study
received our written lifestyle guidance (Cancernet-UK, 2008).
Dietary supplements such as evening primrose oil are popular, but
lack evidence of benefit. Likewise, complementary interventions
such as acupuncture, reflexology and massage, remain unproven
remedies (Richardson et al, 2005). Randomised controlled trials to
evaluate herbal therapies and phytoestrogen supplements have
shown limited benefit, and the consensus among oncologists is
that, if they do work, their oestrogenic effect may be detrimental in
terms of risk of tumour relapse (MacGregor et al, 2005).
The quality of life benefits of AIs over tamoxifen were not
demonstrated within the five large international, published
adjuvant breast cancer studies (Baum, 2001; Coombes et al,
2004; BIG 1-98 Collaborative Group, 2005; Boccardo et al, 2005;
Jakesz et al, 2005), even though the ATAC (Fallowfield et al, 2004a)
and IES trials (Fallowfield et al, 2006) had further specific scrutiny.
There are two possible explanations for this. Firstly in the above
studies, a significant proportion of women fortunately tolerated
both tamoxifen and AI well, so any difference in quality of life
between the two groups was diluted by the ‘no side effect’ cohort;
Second, side effects are more prevalent with AIs (arthralgia and
vaginal dryness) in terms of a quality of life analysis, directly
balance those more likely in the tamoxifen group (night sweats and
vaginal discharge). The fundamental difference in the cohort of the
women evaluated in this paper, is that they all had significant
hot flushes at trial entry. The subsequent 53.7% improvement in
hot flushes, in terms of quality of life and preference, in these
patients outweighed the 17% deterioration in arthropathy.
Another possibility of the significant findings of this study
maybe, albeit unlikely, as a weakness in its open design. Blinding
would have avoided the influence of external sources such as
media reports on the benefits of AIs, but the cost of repackaging
was prohibitive. Although the benefits of switching were over and
above the anticipated placebo effect, a causal effect should ideally
be confirmed by a double-blind, randomised trial. However, it was
in the patient’s interests to be honest about side effects because
they would be taking the medication after the 6-week trial period.
Nevertheless, media activity could have biased a small proportion
of patients towards AI especially in the group who did not notice
much difference between the two drugs. However, the finding that
30% of women chose tamoxifen at 6 weeks or later, and 12% chose
to stop altogether, suggest that patients were more than capable
of weighing up the complex issues of risks, benefits and quality of
life, provided they were empowered with the appropriate
experience. Furthermore, citations in the UK media, referring to
AIs (Table 4), increased over the duration of the study (208
letrozole phase, 303 exemestane) (Cision Public Relations,
2005–2007) whereas the percentage of patients choosing an AI
in the two phases was the same, suggesting media reports were not
a strong influence on their decision-making.
Another criticism of the open design may potentially be
inadvertent physician bias. To diminish this risk, all
questionnaires were completed outside the clinic environment,
and returned to the hospital by post. There did, however, appear to
be a change in physician’s attitudes to the trial entry over the
2-year recruitment period. Despite the eligibility criteria being
the same, the intensity of hot flushes (HFS) at trial entry was
slightly lower in the later, exemestane group at entry. This
probably reflected changing attitudes in clinicians and patients to
switching to AIs as the international evidence emerged. This trend,
although not affecting the statistical power, results and conclusion
did highlight that the quality of life benefits of switching applies
both to patients who had either severe hot flushes (HFS mean 97)
or moderate hot flushes (HFS mean 70.7).
Despite these caveats in trial design, its strength is that the
issues raised very much reflect those confronting patients with
breast cancer and oncologists on a daily basis. The reality that only
two tamoxifen-intolerant women declined trial entry strongly
suggests that these findings reflect routine clinical practise. It was
also reassuring to report that 99% of patients in the study
indicated that they greatly appreciated the opportunity to
experience both drugs: implementing a crossover manoeuvre into
clinical practise is likely to be widely accepted and appreciated.
This trial also highlights patient’s capacity and enthusiasm, if
empowered with personal experiences, to choose which drug best
fits their own daily lives, particularly trading off lower hot flushes
for higher arthralgia. The ability to share decisions with their
clinicians has previously been a factor associated with improved
psychological wellbeing, satisfaction and compliance (Thomas
et al, 1999, 2000, 2004).
Although there was a statistical benefit in favour of AIs, it must
be emphasised that a significant minority of the women felt worse
on AIs. This resulted in 10% switching back to tamoxifen and 12%
of participants withdrawing from hormones altogether, and, no
doubt, another group who had considered switching back, but
decided to remain on their chosen drug. In either scenario,
patients required considerable discussion with their clinicians
within longer and more frequent consultations, which prevented
referral for follow up back to their general practitioners, and has
resource implications for breast clinics.
To conclude, despite the limitations of an open design, these
data suggest that patients suffering significant side effects on
adjuvant tamoxifen should be given the opportunity to try an AI,
as in this study the majority had an improved level of hot flushes,
quality of life and mood. This trial highlights patient’s capacity and
enthusiasm, if empowered with personal experiences, to share
decisions with their clinicians and choose which drug best fits their
lives, particularly trading off lower hot flushes for higher
arthralgia. This manoeuvre is likely to lead to a better quality of
life for women receiving adjuvant hormone therapies, but will
require greater resources for more frequent and more in-depth
follow-up consultations.
Table 4 UK media citations for aromatase inhibitors for the duration of
the study
Key search words 01/03/05–30/11/05 01/12/05–28/02/07
Arimidex 127 129
Aromasin 40 67
Femara 41 107
Any AI 208 303
Courtesy of Cision Public Relations Ltd.
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